EcoDrugPlus

Phosphodiesterase 4a, Camp-Specific

Ensembl ID : ENSDARG00000032344
Gene Symbol: PDE4A
7 Enzyme and pathways 5 Cross references
187 Possible Orthologues:

Phosphodiesterase 4b, Camp-Specific A

Ensembl ID : ENSDARG00000032868
Gene Symbol: PDE4BA
6 Enzyme and pathways 5 Cross references
229 Possible Orthologues:

Phosphodiesterase 4b, Camp-Specific B

Ensembl ID : ENSDARG00000074233
Gene Symbol: PDE4BB
5 Cross references
224 Possible Orthologues:

Phosphodiesterase 4d, Camp-Specific

Ensembl ID : ENSDARG00000032761
Gene Symbol: PDE4D
7 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSDARG00000051915
Gene Symbol: PDE5AB
4 Enzyme and pathways 5 Cross references
209 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSDARG00000045305
Gene Symbol: PDE7A
4 Enzyme and pathways 5 Cross references
215 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSDARG00000060280
Gene Symbol: PDE9A
4 Enzyme and pathways 5 Cross references
189 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSDARG00000038524
Gene Symbol: PIK3R1
86 Enzyme and pathways 5 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 2 (Beta)

Ensembl ID : ENSDARG00000018060
Gene Symbol: PIK3R2
62 Enzyme and pathways 5 Cross references
190 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 3a (Gamma)

Ensembl ID : ENSDARG00000103038
Gene Symbol: PIK3R3A
5 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 3b (Gamma)

Ensembl ID : ENSDARG00000034409
Gene Symbol: PIK3R3B
36 Enzyme and pathways 5 Cross references
139 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 5

Ensembl ID : ENSDARG00000102762
Gene Symbol: PIK3R5
15 Enzyme and pathways 5 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).